Artiva Biotherapeutics (ARTV) Depreciation & Amortization (CF) (2023 - 2026)
Artiva Biotherapeutics' (ARTV) quarterly Depreciation & Amortization (CF) came in at $666000.0 in Q1 2026, up 6.05% year-on-year from $628000.0 in Q1 2025, and little changed on a QoQ basis from $666000.0 in Q4 2025.
Artiva Biotherapeutics (ARTV) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has 4 years of Depreciation & Amortization (CF) data on file, last reported at $666000.0 in Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) rose 6.05% year-over-year to $666000.0 in Q1 2026; TTM through Mar 2026 was $2.6 million, a 6.59% increase from a year earlier, with the FY2025 full-year figure at $2.6 million, up 6.83% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $666000.0, roughly flat from $666000.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for ARTV reached as high as $666000.0 in Q4 2025 and fell as low as $500000.0 in Q2 2023.
- Historically, Depreciation & Amortization (CF) has averaged $612000.0 across 4 years, with a median of $620500.0 in 2024.
- On a YoY basis, Depreciation & Amortization (CF) climbed as much as 20.6% in 2024 and fell as far as 3.37% in 2024.
- Year by year, Depreciation & Amortization (CF) stood at $594000.0 in 2023, then climbed by 3.37% to $614000.0 in 2024, then rose by 8.47% to $666000.0 in 2025, then changed by 0.0% to $666000.0 in 2026.
- Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $666000.0 in Q1 2026, $666000.0 in Q4 2025, and $662000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Artiva Biotherapeutics | 249.99 Mn | 249.99 Mn | - | 666,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 666,000.00 |
| Mar 31, 2026 | 666,000.00 |
| Dec 31, 2025 | 666,000.00 |
| Dec 31, 2025 | 666,000.00 |
| Sep 30, 2025 | 662,000.00 |
| Sep 30, 2025 | 662,000.00 |
| Jun 30, 2025 | 641,000.00 |
| Jun 30, 2025 | 641,000.00 |
| Mar 31, 2025 | 628,000.00 |
| Mar 31, 2025 | 628,000.00 |
| Dec 31, 2024 | 614,000.00 |
| Dec 31, 2024 | 614,000.00 |
| Sep 30, 2024 | 627,000.00 |
| Sep 30, 2024 | 627,000.00 |
| Jun 30, 2024 | 603,000.00 |
| Jun 30, 2024 | 603,000.00 |
| Mar 31, 2024 | 587,000.00 |
| Mar 31, 2024 | 587,000.00 |
| Dec 31, 2023 | 594,000.00 |
| Dec 31, 2023 | 594,000.00 |